Tavapadon aims to treat Parkinson’s motor symptoms by mimicking dopamine in a once-a-day oral dose. And the pivotal, ...

AbbVie Inc. announced positive data from a third late-stage trial of a treatment for Parkinson’s disease on Monday and said ...

Growing older is the greatest risk factor for acquiring Parkinson’s disease and many people live with symptoms for several years before being diagnosed. Often people in early stages of Parkinson’s ...

AbbVie's experimental drug to treat early Parkinson's disease helped significantly improve patients' ability to carry out ...

There’s still a lot we don’t know about how Parkinson’s disease develops. But one lifestyle intervention already has strong ...

A new study published in the journal of Movement Disorders showed that Parkinson's disease (PD) was found to be independently ...

AbbVie Inc. (NYSE:ABBV) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational ...

Diagnosing Parkinson's in the earliest stages before symptoms become serious is a major challenge in medicine, and digital health company PreciseDx thinks it may have a solution to the problem.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

AbbVie, which in September reported that tavapadon had met the primary and secondary endpoints in a Phase 3 fixed-dose monotherapy trial, said it is on track to file for Food & Drug Administration ...